Special Exhibitions

This is the collection of Special Exhibitions created and curated by WhatisBiotechnology about important people and issues in biotechnology.

The path to DNA sequencing: The life and work of Frederick Sanger

One of the most important tools in medicine today is DNA sequencing. It is not only pivotal to mapping out the human genome, but to understanding the genetic cause of diseases like cancer and in the battle against rise of bacterial resistance to antibiotics. DNA sequencing not only lies at the heart of medicine, but is important to many other aspects of modern life, including forensic science and identifying the paternity of children. Despite its importance, the history of DNA sequencing has received relatively little public attention. The development of the technique all began in the 1940s when a British biochemist, Fred Sanger, began looking for a way to work out the composition of proteins, molecules that are fundamental to every biological process in the body. This exhibition traces the life and work of Sanger highlighting the painstaking and time-consuming steps he took to develop DNA sequencing and the many different areas of medicine where his technique is now being applied. Click here to view the exhibition.

The life story of a biotechnology drug: Alemtuzumab

A third of all new medicines introduced into the world today are monoclonal antibodies, many of which go on to become blockbuster drugs. This exhibition is the story of how one specific monoclonal antibody drug, alemtuzumab (marketed as Campath, MabCampath, Campath 1H and Lemtrada), moved from the laboratory bench through to the clinic and the impact it has had on patients' lives. Just one of many hundreds of monoclonal antibodies, alemtuzumab started life in 1979 not as a drug but as a laboratory tool for understanding the immune system. Within a short time, however, it was being used to improve the success of bone marrow transplants and as a treatment for leukaemia, lymphoma, vasculitis, organ transplants and multiple sclerosis. Highlighting the many twists and turns that alemtuzumab took over time, this exhibition explores the multitude of actors and events involved in the making of a biotechnology drug. Click here to view the exhibition.

A Healthcare Revolution in the Making: The Story of César Milstein and Monoclonal Antibodies

Today monoclonal antibodies are indispensable to medicine. They are not only used as therapeutics, comprising six out of ten of the best selling drugs in the world, but are also critical to unravelling the pathways of disease and integral components of diagnostic tests. Yet, the story of how these unsung microscopic heroes came into the world and helped change healthcare remains largely untold. The journey of monoclonal antibodies all started when an Argentinian émigré called César Milstein arrived at the Laboratory of Molecular Biology in Cambridge, the same laboratory where Watson and Crick discovered the structure of DNA. This exhibition tells the story of how Milstein came to develop monoclonal antibodies and demonstrated their clinical application for the first time. Click here to view the exhibition.

Website design by Silico Research the creative minds behind BioPartnering.

Follow us to keep up with all the new content about the world of biotechnology.